Clinicians & Researchers

You are here

Home

PETAL Network Bibliography

Export 63 results:
Author Title [ Type(Asc)] Year
Filters: First Letter Of Last Name is C  [Clear All Filters]
Manuscript
Gill JKaur, Day J, Renaud S.  2023.  Research Staff COVID-19 Pandemic Survey-Results from the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. COVID and Post-COVID: The Psychological and Social Impact of COVID-19. 3:1528-1543.
Journal Article
Mathews KS, Seitz KP, Vranas KC, Duggal A, Valley TS, Zhao B, Gundel S, Harhay MO, Chang SY, Hough CL.  2021.  Variation in Initial U.S. Hospital Responses to the Coronavirus Disease 2019 Pandemic . Critical Care Medicine.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al..  2021.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.. N Engl J Med. 385(9):790-802.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al..  2021.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.. N Engl J Med. 385(9):777-789.
Self WH, Shotwell MS, Gibbs KW, de Wit M, D Files C, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD et al..  2023.  Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.. JAMA. 329(14):1170-1182.
Self WH, Shotwell MS, Gibbs KW, de Wit M, D Files C, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD et al..  2023.  Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.. JAMA. 329(14):1170-1182.
Carlton EF, Ice E, Barbaro RP, Kampuis L, Moss M, Angus DC, Banner-Goodspeed VM, Ginde AA, Gong MN, Grissom CK et al..  2021.  Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome.. J Crit Care. 64:160-164.
Carlton EF, Ice E, Barbaro RP, Kampuis L, Moss M, Angus DC, Banner-Goodspeed VM, Ginde AA, Gong MN, Grissom CK et al..  2021.  Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome.. J Crit Care. 64:160-164.
Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, Chang SY, Eppensteiner J, Filbin M, Gibbs KW et al..  2020.  Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.. Ann Am Thorac Soc. 17(9):1144-1153.
Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, Chang SY, Eppensteiner J, Filbin M, Gibbs KW et al..  2020.  Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.. Ann Am Thorac Soc. 17(9):1144-1153.
Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, Chang SY, Eppensteiner J, Filbin M, Gibbs KW et al..  2020.  Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.. Ann Am Thorac Soc. 17(9):1144-1153.
Lanspa MJ, Gong MNg, Schoenfeld DA, Lee KTiffany, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM et al..  2019.  Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure.. Ann Am Thorac Soc. 16(3):356-362.
Lanspa MJ, Gong MNg, Schoenfeld DA, Lee KTiffany, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM et al..  2019.  Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure.. Ann Am Thorac Soc. 16(3):356-362.
Jolley SElizabeth, Moss M, Needham DM, Caldwell E, Morris PE, Miller RR, Ringwood N, Anders M, Koo KK, Gundel SE et al..  2017.  Point Prevalence Study of Mobilization Practices for Acute Respiratory Failure Patients in the United States.. Crit Care Med. 45(2):205-215.
Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, D Files C et al..  2021.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.. N Engl J Med. 384(10):905-914.
Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, D Files C et al..  2021.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.. N Engl J Med. 384(10):905-914.
Baron RM, Christman JW, Liu KD, Matthay MA, Self WH, McVerry BJ, Hite RDuncan, Paine R, Wurfel MM, Shapiro NI et al..  2020.  Monitoring Research Blood Sampling in Critically Ill Patients: Avoiding Iatrogenic Anemia.. Am J Respir Crit Care Med. 202(6):885-887.
Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC, Ginde AA, Grissom CK, Janz DR, Jones AE et al..  2018.  Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial.. Ann Emerg Med. 72(4):457-466.
Mayer KP, Palakshappa JA, Peltan IDaniel, Andrew JS, Gundel SJ, Ringwood NJ, Mckeehan J, Hope AA, Rogers AJ, Biehl M et al..  2022.  Functional, imaging, and respiratory evaluation (FIRE) of patients post-hospitalization for COVID-19: protocol for a pilot observational study.. Pilot Feasibility Stud. 8(1):212.
Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM et al..  2022.  Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.. Ann Intern Med. 175(9):1266-1274.
Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM et al..  2022.  Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.. Ann Intern Med. 175(9):1266-1274.
Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM et al..  2022.  Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.. Ann Intern Med. 175(9):1266-1274.
Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM et al..  2022.  Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.. Ann Intern Med. 175(9):1266-1274.
Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, McVerry BJ, Kim KS, Lopes RD, Atassi B et al..  2022.  Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. JAMA. 327(3):227-236.
Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, McVerry BJ, Kim KS, Lopes RD, Atassi B et al..  2022.  Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. JAMA. 327(3):227-236.
Berger JS, Neal MD, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Althouse AD, Lawler PR, McVerry BJ, Kim KS et al..  2023.  Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.. JAMA Netw Open. 6(5):e2314428.
Berger JS, Neal MD, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Althouse AD, Lawler PR, McVerry BJ, Kim KS et al..  2023.  Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.. JAMA Netw Open. 6(5):e2314428.
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR et al..  2020.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial . JAMA.
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR et al..  2020.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial . JAMA.
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR et al..  2020.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial . JAMA.
Han JH, Ginde AA, Brown SM, Baughman A, Collar EM, E Ely W, Gong MN, Hope AA, Hou PC, Hough CL et al..  2021.  Effect of Early High-Dose Vitamin D3 Repletion on Cognitive Outcomes in Critically Ill Adults.. Chest. 160(3):909-918.
Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, Hayden D, Hough CL, Hyzy RC, Khan A et al..  2019.  Early High-Dose Vitamin D for Critically Ill, Vitamin D-Deficient Patients.. N Engl J Med. 381(26):2529-2540.
Iwashyna TJ, Kamphuis LA, Gundel SJ, Hope AA, Jolley S, Admon AJ, Caldwell E, Monahan ML, Hauschildt K, B Thompson T et al..  2021.  Continuing Cardiopulmonary Symptoms, Disability, and Financial Toxicity 1 Month After Hospitalization for Third-Wave COVID-19: Early Results From a US Nationwide Cohort.. J Hosp Med.

Pages